GlassScriptPhysician profile
Dawn C Richardson
NPI 1689012650
$5,101.41
in general payments reported to CMS, 2019-2025
36 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $205 · 2021: $206 · 2022: $284 · 2023: $1,468 · 2024: $1,469 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,087.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.51 | 2021-2025 | |
| Astellas Pharma US INC | $643.97 | 2022-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $587.15 | 2020-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Lilly USA, LLC | $390.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $388.44 | 2019-2025 | |
| Novo Nordisk INC | $240.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.40 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.14 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $131.17 | 2019-2025 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $122.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $117.41 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $112.32 | 2024-2025 | Gemtesa |
| Intuitive Surgical, INC. | $109.67 | 2025 | |
| Shield Therapeutics INC | $95.16 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $92.71 | 2019-2024 | Trintellix |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $91.50 | 2019-2024 | Gardasil 9, Gardasil |
| Axsome Therapeutics, INC. | $82.49 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $64.77 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $57.55 | 2022-2023 | Quviviq |
| Insulet Corporation | $57.15 | 2024 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.84 | 2025 | Caplyta |
| Allergan, INC. | $54.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $50.14 | 2019-2024 | |
| Lundbeck LLC | $43.81 | 2024-2025 | Rexulti |
| Csl Behring | $41.35 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $39.12 | 2019-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $36.40 | 2024-2025 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $30.45 | 2024 | Austedo Xr |
| Axonics, INC. | $28.98 | 2024 | Bulkamid, Axonics |
| Corium, LLC | $26.51 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $19.09 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.84 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $18.70 | 2025 | Koselugo |
| Esperion Therapeutics, INC. | $15.78 | 2025 | Nexletol |
| Seqirus USA INC | $13.72 | 2025 | Flucelvax, Fluad |
| Amarin Pharma, INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.